Implications for Practice
mutated lung cancer, MET-mutated lung cancer
The oral dual MET kinase/OCT-2 inhibitor OMO-1 has an acceptable safety profile at doses up to 250 mg BID and shows preliminary clinical efficacy in pre-selected patients with MET exon 14 skipping mutated lung cancer. The potential immune-modulatory effect of OCT-2 inhibition could be particularly interesting in this population of patients with MET-mutated lung cancer because of the MET-induced immunosuppressive tumor-microenvironment.